tbuckley/cabot-search huggingface dataset:
BPI22-012: How Long Will They Wait? Applying Updated NCCN Criteria to Previously Unqualified Patients Reveals Missed Opportunities for Personalized Cancer Risk Management
Authors: Kelly Bontempo, Chloe Wernecke, Brenna Bentley, Krista Ortega, Jessica Kreamer, Rakesh Patel, Peter Beitsch
Journal: Journal of the National Comprehensive Cancer Network (2022)

"BPI22-012: How Long Will They Wait? Applying Updated NCCN Criteria to Previously Unqualified Patients Reveals Missed Opportunities for Personalized Cancer Risk Management" published on 31 Mar 2022 by National Comprehensive Cancer Network.
Comments on Surgeon-Patient Sex Concordance and Postoperative Outcomes
Authors: Ping-Hao Chiang, Chih-Wei Chen, James Cheng-Chung Wei
Journal: JAMA Surgery (2022)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Surgery HomeNew OnlineCurrent IssueFor Authors Podcast Journals JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Surgery journal
Impact on the legal system of the generalizability crisis in psychology
Authors: Chris R. Brewin
Journal: Behavioral and Brain Sciences (2022)

Abstract Overgeneralizations by psychologists of the research evidence on memory and eyewitness testimony, such as “memory decays with time” or “memories are fluid and malleable,” are beginning to appear in legal judgements and guidance documents, accompanied by unwarranted disparagement of lay beliefs about memory. These overgeneralizations could have significant adverse consequences for the conduct of civil and criminal law.
TRICUSPID PAPILLARY FIBROELASTOMA LEADING TO CHRONIC THROMBOEMBOLIC PULMONARY HYPERTENSION
Authors: Yan Naung Htay, Muhammad Wajih Ullah, Prabhakaran Gopalakrishnan, Awais Mirza, Chander Shekhar, Chadi Bou Serhal, Ataul Qureshi
Journal: Journal of the American College of Cardiology (2022)
A Lesson From Behavioral Economics for Reducing Obstetric Interventions—Placing More Weight on Perceived Gains vs Perceived Losses
Authors: Stefania Triunfo
Journal: JAMA Network Open (2022)

Medical decisions can be extremely complex, relying not only on the physician’s knowledge, experience, and judgment, but also on patient medical history, views, and wishes. In obstetrics, making the better choice is challenging, taking into account the existence of the mother-baby dyad.
Treatment of Livedoid Vasculopathy With Baricitinib
Authors: Xiaoting Song, Ping Tu
Journal: JAMA Dermatology (2022)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Dermatology HomeNew OnlineCurrent IssueFor Authors Podcast Journals JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Dermatology journal
HSR22-175: Impact of ‘Choosing Wisely’ on Unnecessary Staging Imaging in Patients With Early Stage Breast Cancer: A Seer-Medicare Analysis
Authors: Ami Vyas, Gavino Puggioni, Shweta Kamat, Stephen J Kogut
Journal: Journal of the National Comprehensive Cancer Network (2022)

"HSR22-175: Impact of ‘Choosing Wisely’ on Unnecessary Staging Imaging in Patients With Early Stage Breast Cancer: A Seer-Medicare Analysis" published on 31 Mar 2022 by National Comprehensive Cancer Network.
IMPACT OF PERIPHERAL ARTERIAL DISEASE ON OUTCOMES AFTER TRANSCATHETER MITRAL VALVE REPAIR IN HEART FAILURE: FROM THE COAPT TRIAL
Authors: Bahira Shahim, David J. Cohen, Ori Ben-Yehuda, Bjorn Redfors, Saibal Kar, None Kar, D. Scott Lim, Suzanne Arnold, Yanru Li, Joann Lindenfeld, William T. Abraham, Michael J. Mack, Gregg W. Stone
Journal: Journal of the American College of Cardiology (2022)
SOCIAL AND CLINICAL PREDICTORS OF 30-DAY READMISSION AFTER HOSPITALIZATION FOR ACUTE DECOMPENSATED HEART FAILURE: INSIGHT FROM THE NATIONAL READMISSIONS DATABASE
Authors: Ramtej Atluri, Omar Khdeir, Sreeram Yalamanchili, Mouna Kodali, Satyam Krishan, Prajwal Shrestha
Journal: Journal of the American College of Cardiology (2022)
EFFECTIVENESS AND SAFETY OF ASPIRIN IN SECONDARY PREVENTION OF CARDIOVASCULAR OUTCOMES IN PATIENTS WITH CHRONIC KIDNEY DISEASE: A SUBGROUP ANALYSIS OF ADAPTABLE
Authors: Harsh Mehta, Kamal Gupta, Hwasoon Kim, Lisa Wruck, Faraz S. Ahmad, Catherine P. Benziger, Peter M. Farrehi, Saket Girotra, Sunil Kripalani, Daniel Munoz, Tamar Polonsky, Amber Sharlow, Jeffrey Whittle, Adrian F. Hernandez, W. Schuyler Jones
Journal: Journal of the American College of Cardiology (2022)
INTRAVASCULAR SHOCKWAVE LITHOTRIPSY FOR THE TREATMENT OF SEVERELY CALCIFIC RENAL ARTERY STENOSIS AFTER AN INADEQUATELY EXPANDED RENAL STENT IN A PATIENT WITH RENOVASCULAR HYPERTENSION
Authors: Muhammad Ahsan, Tuncay Taskesen, Justin Ugwu, Mohammad Zoraiz Ahsan, Sidra Tahseen, Magdi G.H. Ghali, Mercy One
Journal: Journal of the American College of Cardiology (2022)
Bipolar Metal Flexible Electrospun Fibrous Membrane Based on Metal–Organic Framework for Gradient Healing of Tendon‐to‐Bone Interface Regeneration
Authors: Renhao Yang, Yunlong Zheng, Yin Zhang, Gen Li, Yidong Xu, Yin Zhang, Yang Xu, Chengyu Zhuang, Pei Yu, Lianfu Deng, Wenguo Cui, Yao Chen, Lei Wang
Journal: Advanced Healthcare Materials (2022)

Abstract Metal ions play a significant role in tissue repair, with widely application in clinical treatment. However, the therapeutic effect of metal ions is always limited due to metabolization and narrow repair capability. Here, a bipolar metal flexible electrospun fibrous membrane based on a metal–organic framework (MOF), which is bioinspired by the gradient structure of the tendon‐to‐bone interface, with a combination of regulating osteoblasts differentiation and angiogenesis properties, is constructed successfully by a continuous electrospinning technique and matching the longitudinal space morphology for synchronous regeneration. Furthermore, the MOF, acting as carriers, can not only achieve the sustainable release of metal ions, but promote the osteogenesis and tenogenesis on the scaffold. The in vitro data show that this novel hierarchical structure can accelerate the tenogenesis, the biomineralization, and angiogenesis. Moreover, in the in vivo experiment, the flexible fibrous membrane can promote tendon and bone tissue repair, and fibrocartilage reconstruction, to realize the multiple tissue synchronous regeneration at the damaged tendon‐to‐bone interface. Altogether, this newly developed bipolar metal flexible electrospun fibrous membrane based on a MOF, as a new biomimetic flexible scaffold, has great potential in reconstruct the tissue damage, especially gradient tissue damage.
Supporting Health Care Workers to Address Misinformation on Social Media
Authors: Vineet M. Arora, Eve Bloomgarden, Shikha Jain
Journal: New England Journal of Medicine (2022)

Clinicians who respond to misinformation on social media face obstacles. It's important to train clinicians in dispelling harmful myths, to support those who are attacked, and to ensure that people who spread disinformation are held accountable for the harm they cause.
Comparison of Trials Using Ivermectin for COVID-19 Between Regions With High and Low Prevalence of Strongyloidiasis
Authors: Avi Bitterman, Caitlin Pestana Martins, Ahuva Cices, Makarand Prasad Nadendla
Journal: JAMA Network Open (2022)

A widely cited meta-analysis of randomized clinical trials has claimed ivermectin as an effective treatment for prevention of mortality in COVID-19. However, an unrecognized interaction variable with the relative risk (RR) of mortality may substantially change the appropriate interpretation of this analysis.
Abstract P4-02-08: Amcenestrant in combination with CDK4/6 inhibitor palbociclib demonstrates synergistic anti-tumor activity in ER+ endocrine-resistant breast cancer xenograft models
Authors: Maysoun Shomali, Zhuyan Guo, Jane Cheng, Amy Sullivan, Youssef El-Ahmad, Fangxian Sun, Sukhvinder Sidhu, Joon Sang Lee, Hui Cai, Jack Pollard, Laurent Debussche, Chris Soria, Monsif Bouaboula
Journal: Cancer Research (2022)

Abstract Nearly 70% of newly diagnosed cases of breast cancer (BC) are estrogen receptor positive (ER+) where endocrine therapy is a primary treatment. Despite initial efficacy seen with endocrine therapies, approximately 40% of patients develop acquired resistance which ultimately limits the use of these agents even as most of these tumors continue to require ERα. The strategies to combat these cancers with resistance are not yet defined and represent the next major clinical challenge in ER+ breast cancer. Amcenestrant is an optimized oral SERD (selective estrogen receptor degrader) with potent antagonist and degradation activity irrespective of ESR1 mutational status, and is currently being evaluated as monotherapy and in combination with CDK4/6 inhibitors and other targeted therapies for ER+ breast cancer patients in clinical trials. Here, we report that in preclinical models, amcenestrant achieved significant anti-tumor efficacy/regression as a monotherapy and strong synergistic activity when administered together with the CDK4/6 inhibitor, palbociclib, in subcutaneously xenografted endocrine resistant ER+ BC mouse models: ESR1-Y537S mutant-driven MCF7 tumor and HCI-013 PDX (patient-derived xenograft). Transcriptional profile analysis of xenograft tumor biopsies revealed the modulation of different pathways by SERD and palbociclib and highlighted crosstalk of ER and CDK4 signaling pathways. Interestingly, CDK4/6 inhibition by palbociclib induces partial activation of ER pathways as potential mechanism of tumor escape which is completely abolished by the combination treatment of amcenestrant with palbociclib. Early clinical data also showed that amcenestrant in combination with palbociclib, exhibited a favorable safety profile and encouraging antitumor activity in patients with endocrine resistant, ER+/HER2-, advanced breast cancer, which supports its potential to become a new endocrine backbone therapy for ER+ HER2- breast cancer. In conclusion, amcenestrant is an oral SERD, which exhibits significant anti-tumor activity as a single agent and shows synergistic activity with CDK4/6 inhibitor palbociclib in ER+ BC xenografts preclinically and in early clinical development. Citation Format: Maysoun Shomali, Zhuyan Guo, Jane Cheng, Amy Sullivan, Youssef El-Ahmad, Fangxian Sun, Sukhvinder Sidhu, Joon Sang Lee, Hui Cai, Jack Pollard, Laurent Debussche, Chris Soria, Monsif Bouaboula. Amcenestrant in combination with CDK4/6 inhibitor palbociclib demonstrates synergistic anti-tumor activity in ER+ endocrine-resistant breast cancer xenograft models [abstract]. In: Proceedings of the 2021 San Antonio Breast Cancer Symposium; 2021 Dec 7-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2022;82(4 Suppl):Abstract nr P4-02-08.
DO PATIENTS WITH CARDIAC TRANSPLANTATION HAVE POORER PERIPROCEDURAL OUTCOMES AFTER PERCUTANEOUS CORONARY INTERVENTION?
Authors: Neelkumar Patel, Birendra Amgai, Dhrubajyoti Bandyopadhyay, Adrija Hajra, Sandipan Chakraborty, Zeel Patel, Sagar Ranka, Nikhil Cordeiro, Mazin Khalid
Journal: Journal of the American College of Cardiology (2022)
Role of mass spectrometry-based serum proteomics signatures in predicting clinical outcomes and toxicity in patients with cancer treated with immunotherapy
Authors: Yeonggyeong Park, Min Jeong Kim, Yoonhee Choi, Na Hyun Kim, Leeseul Kim, Seung Pyo Daniel Hong, Hyung-Gyo Cho, Emma Yu, Young Kwang Chae
Journal: Journal for ImmunoTherapy of Cancer (2022)

Immunotherapy has fundamentally changed the landscape of cancer treatment. However, only a subset of patients respond to immunotherapy, and a significant portion experience immune-related adverse events (irAEs). In addition, the predictive ability of current biomarkers such as programmed death-ligand 1 (PD-L1) remains unreliable and establishing better potential candidate markers is of great importance in selecting patients who would benefit from immunotherapy. Here, we focus on the role of serum-based proteomic tests in predicting the response and toxicity of immunotherapy. Serum proteomic signatures refer to unique patterns of proteins which are associated with immune response in patients with cancer. These protein signatures are derived from patient serum samples based on mass spectrometry and act as biomarkers to predict response to immunotherapy. Using machine learning algorithms, serum proteomic tests were developed through training data sets from advanced non-small cell lung cancer (Host Immune Classifier, Primary Immune Response) and malignant melanoma patients (PerspectIV test). The tests effectively stratified patients into groups with good and poor treatment outcomes independent of PD-L1 expression. Here, we review current evidence in the published literature on three liquid biopsy tests that use biomarkers derived from proteomics and machine learning for use in immuno-oncology. We discuss how these tests may inform patient prognosis as well as guide treatment decisions and predict irAE of immunotherapy. Thus, mass spectrometry-based serum proteomics signatures play an important role in predicting clinical outcomes and toxicity.
CONTEMPORARY INCIDENCE AND PREDICTORS OF LEFT VENTRICULAR THROMBUS IN PATIENTS WITH ANTERIOR ACUTE MYOCARDIAL INFARCTION AND NEW ANTERO-APICAL WALL MOTION ABNORMALITIES
Authors: Laurie-Anne Boivin Proulx, Fabrice Ieroncig, Simon-Pierre Demers, Marwa Soltani, Louis Verreault-Julien, Yahya Alansari, Ismahane Ghersi, Charles Massie, Philippe Simard, Lorena Rosca, Jean-Simon Lalancette, Gabriel Massicotte, Annabel A. Chen-Tournoux, Benoit Daneault, Jean-Michel Paradis, Jean Gino Diodati, Nicolas Pranno, E. Marc Jolicoeur, Brian J. Potter, Guillaume Marquis-Gravel
Journal: Journal of the American College of Cardiology (2022)
MER4 endogenous retrovirus correlated with better efficacy of anti-PD1/PD-L1 therapy in non-small cell lung cancer
Authors: Julie Lecuelle, Laure Favier, Cléa Fraisse, Aurélie Lagrange, Coureche Kaderbhai, Romain Boidot, Sandy Chevrier, Philippe Joubert, Bertrand Routy, Caroline Truntzer, Francois Ghiringhelli
Journal: Journal for ImmunoTherapy of Cancer (2022)

Endogenous retroviruses (ERVs) are highly expressed in various cancer types and are associated with increased innate immune response and better efficacy of antiprogrammed death-1/ligand-1 (anti-PD1/PD-L1)-directed immune checkpoint inhibitors (ICI) in preclinical models. However, their role in human non-small cell lung cancer (NSCLC) remains unknown.We conducted a retrospective study of patients receiving ICI for advanced NSCLC in two independent cohorts. ERV expression was determined by RNA sequencing. The primary endpoint was progression-free survival (PFS) under ICI. The secondary endpoint was overall survival (OS) from ICI initiation. We studied expression of 6205 ERVs. Multivariate Cox regression model with lasso penalty was estimated on the training set to select ERVs significantly associated with survival. The predictive power of these ERVs was compared with that of previously described transcriptomic signatures.We studied two independent cohorts of 89 and 70 patients, used as training and validation sets. Clinicopathological characteristics included 75% of patients with non-squamous NSCLC. We selected four ERVs significantly associated with PFS. Only high MER4 ERV was associated with better PFS and OS in both cohorts. From a biological point of view, high MER4 expression is associated with higher infiltration of eosinophils and inflammatory gene signatures, while low MER4 expression is associated with enrichment in metabolism and proliferation signatures. Adding MER4 to previously described transcriptomic signatures of response to ICI improved their predictive power.MER4 ERV expression is useful to stratify risk and predict PFS and OS in patients treated with ICI for NSCLC. It also improves the predictive power of other known transcriptomic signatures.
THE EPIGENETIC BET-INHIBITOR APABETALONE REDUCES CARDIOVASCULAR EVENTS IN PATIENTS WITH TYPE 2 DIABETES, ACUTE CORONARY SYNDROME AND AN ELEVATED ANGULO NON-ALCOHOLIC FATTY LIVER DISEASE FIBROSIS SCORE - EXPLORATORY ANALYSIS OF THE BETONMACE TRIAL
Authors: Peter P. Toth, Gregory G. Schwartz, Stephen J. Nicholls, Jan Johansson, Henry Ginsberg, Kamyar Kalantar-Zadeh, Ewelina Kulikowski, Norman C. Wong, Michael Szarek, Michael Sweeney, Kausik Kumar Ray
Journal: Journal of the American College of Cardiology (2022)
Abstract P4-01-09: The WAVE3 phosphorylation/β-catenin oncogenic signaling axis promotes chemoresistance and cancer stemness in triple negative breast cancer
Authors: Wei Wang, Priyanka Rana, Akram Alkrekshi, Vesna Markovic, Khalid Sossey-Alaoui
Journal: Cancer Research (2022)

Abstract Acquisition of the metastatic phenotype is responsible for the death of ~90% of breast cancer (BC) patients. In fact, metastatic BC is the 2nd leading cause of cancer-related deaths in women in the United States, annually accounting for more than 40,100 deaths and 266,000 new cases of invasive BC. Amongst individual BC subtypes, those classified as TNBCs are especially lethal due to their highly metastatic behavior and propensity to recur rapidly. As a group, TNBCs lack expression of hormone receptors (ER-α and PR) and ErbB2/HER2, which has prevented the development of FDA-approved targeted drug therapies that are effective against this BC subtype. Likewise, recurrent TNBCs frequently acquire resistance to standard-of-care chemotherapeutic agents (e.g., doxorubicin, cyclophosphamides, and taxanes) through mechanisms that remain incompletely understood. We established Wiskott-Aldrich Syndrome Protein-3 (WAVE3) as a novel promoter of TNBC development and metastatic progression. Our recently published studies have shown that WAVE3 phosphorylation regulates the interplay between PI3K, TGF-β, and EGF signaling pathways. In this study, we show that WAVE3 phosphorylation promotes chemotherapy-resistance and cancer stemness in TNBC, both in vitro and in in vivo mouse models. CRISPR/Cas9-mediated inactivation of WAVE3 resulted in inhibition of 2D growth and 3D tumorspheres’ invasion of TNBC cells in vitro, as well as tumor growth and metastasis in vivo. In addition, while re-expression of phospho-active WAVE3 in the WAVE3-deficient TNBC cells restored the oncogenic activity of WAVE3, re-expression of phospho-mutant WAVE3 or the pharmacologic inhibition of WAVE3 phosphorylation did not. Further studies revealed that dual blocking WAVE3 expression or phosphorylation with chemotherapy treatment inhibited the activity and expression of β-catenin. Importantly, a combination of WAVE3-deficiency and chemotherapy suppressed the oncogenic behavior of chemo-resistant TNBC cells, both in vitro and in vivo. This study suggests that a targeted therapeutic strategy against WAVE3 could be effective for the treatment of chemoresistant TNBC tumors. Citation Format: Wei Wang, Priyanka Rana, Akram Alkrekshi, Vesna Markovic, Khalid Sossey-Alaoui. The WAVE3 phosphorylation/β-catenin oncogenic signaling axis promotes chemoresistance and cancer stemness in triple negative breast cancer [abstract]. In: Proceedings of the 2021 San Antonio Breast Cancer Symposium; 2021 Dec 7-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2022;82(4 Suppl):Abstract nr P4-01-09.
ClinGen Variant Curation Interface: a variant classification platform for the application of evidence criteria from ACMG/AMP guidelines
Authors: Christine G. Preston, Matt W. Wright, Rao Madhavrao, Steven M. Harrison, Jennifer L. Goldstein, Xi Luo, Hannah Wand, Bryan Wulf, Gloria Cheung, Mark E. Mandell, Howard Tong, Shaung Cheng, Michael A. Iacocca, Arturo Lopez Pineda, Alice B. Popejoy, Karen Dalton, Jimmy Zhen, Selina S. Dwight, Lawrence Babb, Marina DiStefano, Julianne M. O’Daniel, Kristy Lee, Erin R. Riggs, Diane B. Zastrow, Jessica L. Mester, Deborah I. Ritter, Ronak Y. Patel, Sai Lakshmi Subramanian, Aleksander Milosavljevic, Jonathan S. Berg, Heidi L. Rehm, Sharon E. Plon, J. Michael Cherry, Carlos D. Bustamante, Helio A. Costa
Journal: Genome Medicine (2022)

Abstract Background Identification of clinically significant genetic alterations involved in human disease has been dramatically accelerated by developments in next-generation sequencing technologies. However, the infrastructure and accessible comprehensive curation tools necessary for analyzing an individual patient genome and interpreting genetic variants to inform healthcare management have been lacking. Results Here we present the ClinGen Variant Curation Interface (VCI), a global open-source variant classification platform for supporting the application of evidence criteria and classification of variants based on the ACMG/AMP variant classification guidelines. The VCI is among a suite of tools developed by the NIH-funded Clinical Genome Resource (ClinGen) Consortium and supports an FDA-recognized human variant curation process. Essential to this is the ability to enable collaboration and peer review across ClinGen Expert Panels supporting users in comprehensively identifying, annotating, and sharing relevant evidence while making variant pathogenicity assertions. To facilitate evidence-based improvements in human variant classification, the VCI is publicly available to the genomics community. Navigation workflows support users providing guidance to comprehensively apply the ACMG/AMP evidence criteria and document provenance for asserting variant classifications. Conclusions The VCI offers a central platform for clinical variant classification that fills a gap in the learning healthcare system, facilitates widespread adoption of standards for clinical curation, and is available at https://curation.clinicalgenome.org